These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 17520197)

  • 21. Reduced expression of p53 and cyclin A in intraductal mucin-hypersecreting neoplasm of the pancreas compared with usual pancreatic ductal adenocarcinoma.
    Mukawa K; Kawa S; Aoki Y; Zhai Y; Nikaido T
    Am J Gastroenterol; 1999 Aug; 94(8):2263-7. PubMed ID: 10445560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas.
    Sakamoto H; Kuboki Y; Hatori T; Yamamoto M; Sugiyama M; Shibata N; Shimizu K; Shiratori K; Furukawa T
    Mod Pathol; 2015 Feb; 28(2):261-7. PubMed ID: 25081753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
    Adsay NV; Basturk O; Cheng JD; Andea AA
    Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cystic papillary pattern in pancreatic ductal adenocarcinoma: a heretofore undescribed morphologic pattern that mimics intraductal papillary mucinous carcinoma.
    Kelly PJ; Shinagare S; Sainani N; Hong X; Ferrone C; Yilmaz O; Fernández-del Castillo C; Lauwers GY; Deshpande V
    Am J Surg Pathol; 2012 May; 36(5):696-701. PubMed ID: 22367300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas.
    Wada K
    J Hepatobiliary Pancreat Surg; 2002; 9(1):76-85. PubMed ID: 12021900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas.
    Miyasaka Y; Nagai E; Yamaguchi H; Fujii K; Inoue T; Ohuchida K; Yamada T; Mizumoto K; Tanaka M; Tsuneyoshi M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4371-7. PubMed ID: 17671118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
    Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
    J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the cytologic features of noninvasive ductal carcinomas of the pancreas: differences from invasive ductal carcinoma.
    Hara H; Suda K
    Am J Clin Pathol; 2008 Jan; 129(1):115-29. PubMed ID: 18089497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
    Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
    Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas.
    Schoedel KE; Finkelstein SD; Ohori NP
    Diagn Cytopathol; 2006 Sep; 34(9):605-8. PubMed ID: 16900481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
    Basturk O; Berger MF; Yamaguchi H; Adsay V; Askan G; Bhanot UK; Zehir A; Carneiro F; Hong SM; Zamboni G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Balci S; Allen P; Ikari N; Takeuchi S; Akagawa H; Kanno A; Shimosegawa T; Morikawa T; Motoi F; Unno M; Higuchi R; Yamamoto M; Shimizu K; Furukawa T; Klimstra DS
    Mod Pathol; 2017 Dec; 30(12):1760-1772. PubMed ID: 28776573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
    Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
    Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma.
    Lüttges J; Zamboni G; Longnecker D; Klöppel G
    Am J Surg Pathol; 2001 Jul; 25(7):942-8. PubMed ID: 11420467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraductal papillary mucinous neoplasms of the pancreas: pathology and molecular genetics.
    Adsay NV
    J Gastrointest Surg; 2002; 6(5):656-9. PubMed ID: 12399051
    [No Abstract]   [Full Text] [Related]  

  • 35. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
    Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
    J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraductal papillary mucinous tumor of the pancreas in 2 twin brothers diagnosed as having the carney complex.
    Pery C; Avallone S; Regenet N; Coron E; Le Borgne J
    Pancreas; 2009 Mar; 38(2):237-9. PubMed ID: 19238031
    [No Abstract]   [Full Text] [Related]  

  • 37. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas.
    Uehara H; Nakaizumi A; Ishikawa O; Iishi H; Tatsumi K; Takakura R; Ishida T; Takano Y; Tanaka S; Takenaka A
    Gut; 2008 Nov; 57(11):1561-5. PubMed ID: 18477671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Where and when does pancreatic carcinoma start?
    Lüttges J; Hahn S; Klöppel G
    Med Klin (Munich); 2004 Apr; 99(4):191-5. PubMed ID: 15085289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression changes associated with the progression of intraductal papillary mucinous neoplasms.
    Jury RP; Thibodeau BJ; Fortier LE; Geddes TJ; Ahmed S; Pruetz BL; Farinola MA; Wilson GD
    Pancreas; 2012 May; 41(4):611-8. PubMed ID: 22273699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
    Hiraoka N; Onozato K; Kosuge T; Hirohashi S
    Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.